Drug intelligence / Profile preview

xinmailong

Development stage: Phase 2
Lead developer: Yunnan Tengyao Pharmaceutical
Modality: Peptides, Small Molecules
Administration: Intravenous

Overview

Xinmailong is a bioactive peptide preparation extracted and purified from the American cockroach (*Periplaneta americana*). Approved by the State Pharmaceutical Administration of China, it is primarily indicated for the treatment of chronic heart failure. The drug consists of complex nucleoside bases and binding amino acids. Clinical studies have demonstrated its efficacy in reducing brain natriuretic peptide (BNP) levels, improving cardiac diastolic function, and mitigating chemotherapy-induced cardiotoxicity in breast cancer patients. It is also being investigated for its role in treating sepsis-induced myocardial dysfunction (SIMD).

Brand names: Xinmailong
Other names: Xinmailong InjectionXinmailong Zhusheye

Targets

CaV3 (Caveolin-3)

Beyond the preview

Go deeper on xinmailong.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on xinmailong.

Explore the full profile